Toboroz
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
NCT07668336· 3. fázis· Eli Lilly and Company· Forrás
Contact: Jun Mori (principal investigator)
Fut, nem toboroz
A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain Tumours
NCT07441707· 1. fázis· Ipsen· Forrás
Toboroz
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
NCT07063745· 2/3. fázis· Bristol-Myers Squibb· Forrás
Contact: Ayako Tanaka, Site 0239
Toboroz
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
NCT07128199· 3. fázis· Taiho Oncology, Inc.· Forrás
Contact: Taiho Oncology, Inc.
Toboroz
A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy
NCT07227857· 1/2. fázis· Institut de Recherches Internationales Servier· Forrás
Contact: Shin Okazaki
Toboroz
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
NCT06899126· 3. fázis· Daiichi Sankyo· Forrás
Fut, nem toboroz
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
NCT06872125· 3. fázis· Stoke Therapeutics, Inc· Forrás
Fut, nem toboroz
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06914895· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT06875310· 3. fázis· Mirati Therapeutics Inc.· Forrás
Contact: Yuki Nakatani, Site 0297
Toboroz
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
NCT06801834· 3. fázis· Gilead Sciences· Forrás
Meghívásos bevonás
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)
NCT06908226· 3. fázis· Longboard Pharmaceuticals· Forrás
Toboroz
Study to ONO-4538 in Patients With Rhabdoid Tumor
NCT06622941· 2. fázis· Ono Pharmaceutical Co., Ltd.· Forrás
Contact: North America Clinical Trial Support Desk
Toboroz
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
NCT06672939· 3. fázis· Eli Lilly and Company· Forrás
Contact: Jun Mori (principal investigator)
Toboroz
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
NCT06672549· 3. fázis· Eli Lilly and Company· Forrás
Contact: Jun Mori (principal investigator)
Fut, nem toboroz
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)
NCT06719141· 3. fázis· Longboard Pharmaceuticals· Forrás
Fut, nem toboroz
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
NCT06413706· 2. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
NCT06660394· 3. fázis· Longboard Pharmaceuticals· Forrás
Fut, nem toboroz
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06564142· 3. fázis· Alpine Immune Sciences Inc, A Subsidiary of Vertex· Forrás
Fut, nem toboroz
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
NCT05973773· 3. fázis· Taiho Oncology, Inc.· Forrás
Toboroz
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
NCT05580562· 3. fázis· Jazz Pharmaceuticals· Forrás
Contact: Keiko Okada
Toboroz
Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
NCT05327894· 3. fázis· Princess Maxima Center for Pediatric Oncology· Forrás
Contact: Lieke van den Wildenberg
Fut, nem toboroz
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
NCT05183035· 3. fázis· PedAL BCU, LLC· Forrás
Fut, nem toboroz
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT04965493· 3. fázis· Loxo Oncology, Inc.· Forrás
Fut, nem toboroz
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
NCT04656652· 3. fázis· Daiichi Sankyo· Forrás
Toboroz
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
NCT04613596· 2/3. fázis· Mirati Therapeutics Inc.· Forrás
Contact: Haruko Daga, Site Daga, H.
Toboroz
A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome
NCT04608110· 1. fázis· Taiho Pharmaceutical Co., Ltd.· Forrás
Contact: Hematology
Fut, nem toboroz
A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer
NCT04036682· 1/2. fázis· Cullinan Therapeutics Inc.· Forrás
Toboroz
Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer
NCT04288999· 3. fázis· National Cancer Center Hospital East· Forrás
Contact: Kiyoshi Maeda
Fut, nem toboroz
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer
NCT03456076· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
NCT03067181· 3. fázis· Children's Oncology Group· Forrás
Contact: Akihiro Fujino (principal investigator)
Fut, nem toboroz
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
NCT03157128· 1/2. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
NCT03052608· 3. fázis· Pfizer· Forrás
Toboroz
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
NCT03093116· 1/2. fázis· Turning Point Therapeutics, Inc.· Forrás
Contact: Haruko Daga, Site 6605
Toboroz
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
NCT02735707· 3. fázis· UMC Utrecht· Forrás
Contact: Cameron Green, MSc
Fut, nem toboroz
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
NCT02411448· 3. fázis· Eli Lilly and Company· Forrás